Orbicular which develops specialty or complex generics for global pharmaceutical markets will utilize the capital for accelerating the development of product pipeline.
Orbicular has developed a robust pipeline of niche products in the specialty generics space positioning them as an ideal partner for global generic players targeting regulated markets.
The specialty generics has a market size of $60 billion and is rapidly expanding, driven by increasing demand for cost-effective alternatives to complex and high-cost branded medications.
“Under the able leadership of Dr. M.S. Mohan, Orbicular has developed a strong product pipeline for the regulated markets,” said Visalakshi Chandramouli, managing partner, Tata Capital Healthcare Fund.
“This investment reinforces our fund’s core philosophy of identifying the big shifts in the industry and being a “capital plus” partner to our companies.Ambit acted as the exclusive financial advisor to Orbicular and its shareholders on this transaction. TCHF is a growth oriented private equity fund focused on the healthcare and lifesciences sector in India. TCHF has raised $200 million across two funds – TCHF I (2012) and TCHF II (2022). Across both the funds, TCHF has invested in 18 companies, and has successfully exited 6 companies.
